415 related articles for article (PubMed ID: 35635048)
1. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review.
Aghemo A; Alekseeva OP; Angelico F; Bakulin IG; Bakulina NV; Bordin D; Bueverov AO; Drapkina OM; Gillessen A; Kagarmanova EM; Korochanskaya NV; Kucheryavii UA; Lazebnik LB; Livzan MA; Maev IV; Martynov AI; Osipenko MF; Sas EI; Starodubova A; Uspensky YP; Vinnitskaya EV; Yakovenko EP; Yakovlev AA
Ann Med; 2022 Dec; 54(1):1548-1560. PubMed ID: 35635048
[TBL] [Abstract][Full Text] [Related]
2. Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.).
Paik JM; Eberly KE; Kabbara K; Harring M; Younossi Y; Henry L; Verma M; Younossi ZM
Ann Hepatol; 2023; 28(4):101108. PubMed ID: 37088421
[TBL] [Abstract][Full Text] [Related]
3. Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review.
Gillessen A; Schmidt HH
Adv Ther; 2020 Apr; 37(4):1279-1301. PubMed ID: 32065376
[TBL] [Abstract][Full Text] [Related]
4. Chronic liver disease and management with silymarin: an introductory review of a clinical case collection.
Angelico F
Drugs Context; 2024; 13():. PubMed ID: 38332944
[TBL] [Abstract][Full Text] [Related]
5. Etiological Patterns, Liver Fibrosis Stages and Prescribing Patterns of Hepato-Protective Agents in Indian Patients with Chronic Liver Disease.
Choudhuri G; Chaudhari S; Pawar D; Roy DS
J Assoc Physicians India; 2018 Dec; 66(12):58-63. PubMed ID: 31315327
[TBL] [Abstract][Full Text] [Related]
6. Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy.
Zhang CY; Liu S; Yang M
World J Hepatol; 2023 Feb; 15(2):180-200. PubMed ID: 36926234
[TBL] [Abstract][Full Text] [Related]
7. Chronic Liver Disease and Silymarin: A Biochemical and Clinical Review.
Tighe SP; Akhtar D; Iqbal U; Ahmed A
J Clin Transl Hepatol; 2020 Dec; 8(4):454-458. PubMed ID: 33447529
[TBL] [Abstract][Full Text] [Related]
8. Silymarin in the prevention and treatment of liver diseases and primary liver cancer.
Féher J; Lengyel G
Curr Pharm Biotechnol; 2012 Jan; 13(1):210-7. PubMed ID: 21466434
[TBL] [Abstract][Full Text] [Related]
9. Chronic liver disease and oxidative stress - a narrative review.
Seen S
Expert Rev Gastroenterol Hepatol; 2021 Sep; 15(9):1021-1035. PubMed ID: 34176419
[No Abstract] [Full Text] [Related]
10. Hepatoprotective effect of silymarin on fructose induced nonalcoholic fatty liver disease in male albino wistar rats.
Mengesha T; Gnanasekaran N; Mehare T
BMC Complement Med Ther; 2021 Mar; 21(1):104. PubMed ID: 33785007
[TBL] [Abstract][Full Text] [Related]
11. A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases.
Ezhilarasan D; Lakshmi T
Oxid Med Cell Longev; 2022; 2022():9233650. PubMed ID: 35602098
[TBL] [Abstract][Full Text] [Related]
12. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).
Méndez-Sánchez N; Díaz-Orozco LE
Med Sci Monit; 2021 Jul; 27():e933860. PubMed ID: 34248137
[TBL] [Abstract][Full Text] [Related]
13. Beneficial and Paradoxical Roles of Anti-Oxidative Nutritional Support for Non-Alcoholic Fatty Liver Disease.
Uchida D; Takaki A; Adachi T; Okada H
Nutrients; 2018 Jul; 10(8):. PubMed ID: 30060482
[TBL] [Abstract][Full Text] [Related]
14. [Silymarin in the treatment of chronic liver diseases: past and future].
Fehér J; Lengyel G
Orv Hetil; 2008 Dec; 149(51):2413-8. PubMed ID: 19073452
[TBL] [Abstract][Full Text] [Related]
15. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years.
Federico A; Dallio M; Loguercio C
Molecules; 2017 Jan; 22(2):. PubMed ID: 28125040
[TBL] [Abstract][Full Text] [Related]
16. Silymarin and hepatocellular carcinoma: a systematic, comprehensive, and critical review.
Mastron JK; Siveen KS; Sethi G; Bishayee A
Anticancer Drugs; 2015 Jun; 26(5):475-86. PubMed ID: 25603021
[TBL] [Abstract][Full Text] [Related]
17. Hepatoprotective Effect and Synergism of Bisdemethoycurcumin against MCD Diet-Induced Nonalcoholic Fatty Liver Disease in Mice.
Kim SB; Kang OH; Lee YS; Han SH; Ahn YS; Cha SW; Seo YS; Kong R; Kwon DY
PLoS One; 2016; 11(2):e0147745. PubMed ID: 26881746
[TBL] [Abstract][Full Text] [Related]
18. Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives.
Salomone F; Godos J; Zelber-Sagi S
Liver Int; 2016 Jan; 36(1):5-20. PubMed ID: 26436447
[TBL] [Abstract][Full Text] [Related]
19. Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD.
Liang J; Liu Y; Liu J; Li Z; Fan Q; Jiang Z; Yan F; Wang Z; Huang P; Feng N
J Nanobiotechnology; 2018 Sep; 16(1):64. PubMed ID: 30176941
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases.
Lee HA; Chang Y; Sung PS; Yoon EL; Lee HW; Yoo JJ; Lee YS; An J; Song DS; Cho YY; Kim SU; Kim YJ
Clin Mol Hepatol; 2022 Jul; 28(3):425-472. PubMed ID: 35850495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
